Petrus-Krankenhaus

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer4 trials
• Idiopathic pulmonary fibrosis4 trials
• COPD2 trials
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• High blood pressure1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial
• Pulmonary arterial hypertension1 trial

Phase

• Phase 310 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Recruiting7 trials
• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials

Lead sponsor

• AIO-Studien-gGmbH2 trials
• Dominik Paul Modest2 trials
• GlaxoSmithKline2 trials
• AstraZeneca AB1 trial
• BeOne Medicines1 trial
• and 6 more

Running trials

• Not yet recruiting

  Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

  NCT07715396· Phase 3· AIO-Studien-gGmbH· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

  NCT05820841· Phase 3· Universität des Saarlandes· Source

• Active, not recruiting

  Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

  NCT05118724· Phase 2· AIO-Studien-gGmbH· Source

• Recruiting

  Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

  NCT05008809· Phase 3· Dominik Paul Modest· Source

• Active, not recruiting

  A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

  NCT04002297· Phase 3· BeOne Medicines· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• COPD2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Technische Universitat Dresden· Source